HyBryte Skin Cancer Drug Fails Key Test – Soligenix FLASH2 Trial Halted
Soligenix stopped HyBryte CTCL trial early as it didn’t work well, though it was safe; company will review data and options.
/ 352 items
#XY Event-Driven Stocks↓
PFS Triumph or OS Flop? Why CMPX Shares Plunged Despite Positive Cancer Results
Compass Therapeutics fell after cancer drug improved outcomes but failed to show clear survival benefit due to patient crossover.
Veradermics’ Oral Hair Loss Pill Scores Major Win in Late-Stage Trial
Veradermics’ hair pill VDPHL01 showed strong results, growing 30+ hairs/cm in trials, safe, and may become a new baldness treatment.
Oruka’s Long-Acting Psoriasis Drug Hits 63.5% Complete Skin Clearance in Mid-Stage Trial
Oruka’s new psoriasis drug cleared skin in most patients with few side effects and may need only yearly injections.
Eli Lilly Acquires Ajax Therapeutics to Advance New Treatment for Rare Blood Cancers
Eli Lilly buys Ajax to develop a new pill for rare blood cancers that may work longer and better than current treatments.
Sun Pharma Acquires Organon in $11.75 Billion Deal – India’s Biggest Overseas Pharma Buy
Sun Pharma will buy Organon for $11.75B, boosting global reach, women’s health, and specialty drugs, and creating a $12.4B annual revenue pharma giant.